▎Edited by the WuXi AppTec content team

News on October 24, Symbionics announced the completion of a 30 million yuan angel round of financing. This round of financing was led byKunlun CapitalExclusive Investment. Symbionics, founded in 2023, is a brain-computer interface startup focused on research and development.Flexible Brain-Computer Interface Device. The funds from this round of financing will be mainly used for the company's team expansion, basic platform construction, technical product finalization, and to promote the development of flexible brain-computer interface technology.

Brain-computer interface technology refers to the interpretation of neural electrical activity signals to achieve information exchange between external devices and the brain. This technology has rapidly advanced in recent years, offering hope for those who have lost the ability to move or speak due to nerve damage to regain communication with the outside world, and potentially complete certain bodily functions through thought.

Image Source: 123RF

According to the signal acquisition pathway, brain-computer interfaces can be divided into two main categories: non-invasive and invasive brain-computer interfaces. For invasive brain-computer interfaces, neural electrodes are the key components that need to be implanted in the human brain for the long term. Ideal neural electrodes must be capable of collecting high-quality neural signals with long-term stability. According to a press release from Symbionics,The company's flexible electrode technology has currently achieved long-term stable collection of high-quality, single-cell resolution neural signals. It can evade immune rejection in living organisms, and the implanted electrodes exhibit high biocompatibility and neural interface stability, addressing many issues associated with traditional rigid electrodes.

Symbionics CEO Wu Shu stated that brain-computer interface (BCI) is a technology with tremendous potential, offering not only new treatment options for various medical conditions but also envisioning a future with a more seamless form of human-computer interaction. Symbionics possesses key technologies and product development capabilities in BCI and greatly appreciates Kunlun Capital for sharing their vision of changing the world through BCI technology.

Kunlun Capital stated that, starting from improving the quality of life for disabled patients, brain-computer interfaces ultimately have the potential to transform the paradigm of human-machine interaction. As a key technology of significant value, the development of brain-computer interfaces requires a team capable of standing at the forefront of global science and technology while being able to implement practices locally in China. The Symbionics team originates from well-known laboratories in the field and has achieved local implementation in China within a short period. In the field of brain-computer interface development, Kunlun Capital has high expectations for the team's continuous innovation capabilities.